<div><div></div><div><span><p><span>Nika Pharmaceuticals, Inc. reported first-quarter 2026 results in its 10-Q filing showing a net loss for the quarter. Revenue and net loss each totaled ($13.36K) versus ($12.95K) in the prior-year quarter, while diluted earnings per share were $0.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>($13.36K)</span></td><td><span>($12.95K)</span></td><td><span>(3.2%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($13.36K)</span></td><td><span>($12.95K)</span></td><td><span>(3.2%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>$0</span></td><td><span>$0</span></td><td><span>—</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Revenue”. ² Reported as “Net Loss”. ³ Reported as “Loss per share, basic and diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Strategic partnerships: The company signed multiple long-term exclusive agreements (TNG, Carotilen, Physiolong, IPF platform) to expand its product pipeline and rights.</span></li><li><span>Manufacturing buildout: Nika Europe is pursuing a GMP vial production line and planning a pharmaceutical factory to produce injections, tablets and other forms.</span></li><li><span>Geographic and asset moves: Expanded presence through Nika Europe, acquired technologies and experienced temporary ownership changes affecting its European production foothold.</span></li><li><span>Product pipeline momentum: Acquisitions include technologies for three generics and one supplement; a production agreement for ITV-1 is expected to generate per-set margins.</span></li><li><span>Funding and operations: The company had no revenue-generating operations yet and has been funded by related-party loans while preparing production capacity and regulatory steps.</span></li></ul><p><span>Original SEC Filing: </span>NIKA PHARMACEUTICALS, INC [ NIKA ] - 10-Q - May. 12, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

IBBQ

562050

<p>Nika Pharmaceuticals, Inc. reported a net loss of $13.36K for Q1 2026, with revenue unchanged from the prior year. The company has signed long-term agreements to enhance its product pipeline and is expanding its manufacturing capabilities in Europe. Despite no revenue-generating operations yet, Nika is preparing for production and has been funded by related-party loans. The diluted EPS remains at $0. The company is also pursuing acquisitions to bolster its product offerings.</p>

TradingView

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

E Fund CSI 300 Health Care ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

iShares Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

ChinaAMC CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

NIKA PHARMACEUTICALS, INC 1Q 2026: Revenue ($13.36K), Net income ($13.36K), EPS $0— 10-Q Summary